Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 17/20 | 0.52 |
| ▸ | DDB1 | Q16531 | 10/20 | 0.52 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | GSPT1 | P15170 | 8/20 | 0.38 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.35 |
| ▸ | NEK1 | Q96PY6 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23832611 | 0.91 | CRBN (0.52) | CRBNDDB1DRD2GSPT1ACHE | |
| SCHEMBL30289258 | 0.91 | CRBN (0.53) | CRBNDDB1DRD2GSPT1IKZF3 | |
| SCHEMBL30289015 | 0.89 | DDB1 (0.51) | CRBNDDB1DRD2 | |
| SCHEMBL30289201 | 0.87 | DDB1 (0.53) | CRBNDDB1DRD2 | |
| SCHEMBL26699653 | 0.86 | DDB1 (0.56) | CRBNDDB1 | |
| SCHEMBL27067107 | 0.86 | CRBN (0.47) | CRBNDDB1DRD2GSPT1 | |
| SCHEMBL23832650 | 0.85 | CRBN (0.48) | CRBNDDB1DRD2GSPT1IKZF3 | |
| SCHEMBL30289264 | 0.84 | DDB1 (0.57) | CRBNDDB1DRD2 | |
| SCHEMBL23832613 | 0.84 | DDB1 (0.59) | CRBNDDB1 | |
| SCHEMBL23841932 | 0.84 | CRBN (0.58) | CRBNDDB1IKZF3ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12528785-B2 | MDM2 degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| US-20240424110-A1 | MDM2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-12-26 | — | — | US | disclosed |
| US-11932624-B2 | MDM2 degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2024-03-19 | — | — | US | disclosed |
| US-20240025878-A1 | MDM2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20240025878-A1 | MDM2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-01-25 | — | — | US | disclosed |
| EP-4121043-A1 | MDM2 DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2023-01-25 | — | — | EP | disclosed |
| WO-2021188948-A1 | MDM2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2021-09-23 | — | — | WO | disclosed |
| WO-2021188948-A1 | MDM2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2021-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240025878-A1 | MDM2 DEGRADERS AND USES THEREOF | MDM2, TP53, MDM4 | CRBN 93/4885DDB1 269/4885DRD2 4088/4885 |
| US-20240424110-A1 | MDM2 DEGRADERS AND USES THEREOF | MDM2, USP2, MYCBP2 | CRBN 101/4885DDB1 255/4885DRD2 3978/4885 |
| US-12528785-B2 | MDM2 degraders and uses thereof | MDM2, ADRM1, RBX1 | CRBN 18/4885DDB1 243/4885DRD2 3318/4885 |
| US-11932624-B2 | MDM2 degraders and uses thereof | MDM2, TP53, MDM4 | CRBN 93/4885DDB1 269/4885DRD2 4088/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.